Teva Deals Early On US Auvelity Generic, Agreeing To At Least 13-Year Freeze
Auvelity Shielded By More Than 100 Patents; Peak Sales Tipped To Exceed $2.5bn
Teva will have to wait until the end of the next decade to launch its proposed generic version of Axsome Therapeutics’ Auvelity treatment for MDD.
